Skip to main content

Table 2 Effect of Carvedilolon Gross Morphology

From: Chronic treatment with Carvedilol improves ventricular function and reducesmyocyte apoptosis in an animal model of heart failure

  HW (kg) BW (kg) HW/BW (%) LV vol (ml)
Control (n = 13) 0.018 ± 0.001 4.36# ± 0.16 0.4 ± 0.013 0.24• ± 0.04
Cont 1 (n = 11) 0.018 ± 0.001 5.3# ± 0.14 0.35 ± 0.016 0.37• ± 0.06
Cont 20 (n = 10) 0.02 ± 0.001 5.65# ± 0.09 0.35 ± 0.008 0.37• ± 0.04
DCM 0 (n = 18) 0.017 ± 0.001 2.61 ± 0.23 0.64 ± 0.049 9.36 ± 2.0
DCM 1 (n = 13) 0.019 ± 0.001 3.07# ± 0.29 0.60 ± 0.05 6.28• ± 2.54
DCM 20 (n = 12) 0.019 ± 0.001 3.26# ± 0.29 0.58 ± 0.078 5.38• ± 1.95
  1. HW: heart weightp ≤ 0.01 compared to non-treated DCM group;BW: body weight #p < 0.001 compared to non-treated DCM group;HW/BW ratio p < 0.04 compared to non-treated DCM group; LV vol: atria were removed and the left ventricles were arrested in diastole and filled with saline • p ≤ 0.008 compared to non-treated DCM. Note the increase in body weight and heart weight with carvedilol treatment. This resulted in a significant improvement in HW/BW ratio despite having heavier hearts. The reduction in heart weight seen in the non-treated DCM group was associated with a higher incidence of apoptosis while the increased heart weight in hearts from DCM animals treated with carvedilol was associated with a lower incidence of apoptosis.